Valuation: Moderna, Inc.

Market Cap 22.62B 19.9B 18.49B 17B 31.88B 2,191B 32.46B 221B 86.22B 1,069B 84.94B 83.1B 3,708B P/E 2026 *
-6.59x
P/E 2027 * -12x
Enterprise Value 19.22B 16.9B 15.7B 14.44B 27.08B 1,861B 27.57B 188B 73.24B 908B 72.15B 70.59B 3,149B EV / Sales 2026 *
9.17x
EV / Sales 2027 * 8.06x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-1.81%
1 week-9.71%
Current month-18.58%
1 month-6.52%
3 months+7.89%
6 months+17.06%
Current year+93.35%
1 week 56.28
Extreme 56.275
62.43
1 month 56.28
Extreme 56.275
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%-9.71%+64.46%-54.90% 22.62B
+0.11%-3.98%+13.89%-11.26% 66.32B
+0.62%+2.17%+36.67%+200.29% 52.6B
+0.51%+37.90%+37.90%+37.90% 43.27B
-1.32%-7.38%-57.63%-57.10% 38.64B
+1.46%-3.97%+53.17%-27.51% 29.62B
+0.78%+0.03%+65.07%+81.90% 23.31B
-1.21%+1.12%+1.98%+170.93% 20.22B
-1.03%-1.86%+60.48%+121.72% 16.29B
+0.33%+3.28%+79.54%+142.98% 16.26B
Average -0.16%-2.28%+35.55%+60.50% 32.92B
Weighted average by Cap. -0.01%-2.31%+27.74%+51.15%

Financials

2026 *2027 *
Net sales 2.1B 1.84B 1.71B 1.57B 2.95B 203B 3.01B 20.47B 7.98B 98.96B 7.87B 7.7B 343B 2.55B 2.24B 2.08B 1.92B 3.6B 247B 3.66B 24.93B 9.72B 121B 9.58B 9.37B 418B
Net income -3.41B -3B -2.79B -2.56B -4.8B -330B -4.89B -33.31B -12.99B -161B -12.8B -12.52B -559B -1.85B -1.63B -1.51B -1.39B -2.61B -179B -2.65B -18.07B -7.05B -87.35B -6.94B -6.79B -303B
Net Debt -3.41B -3B -2.78B -2.56B -4.8B -330B -4.89B -33.28B -12.98B -161B -12.79B -12.51B -558B -2.05B -1.81B -1.68B -1.54B -2.89B -199B -2.95B -20.06B -7.82B -96.98B -7.71B -7.54B -336B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
23/07/26 US$57.02 -1.81% 4,695,588
22/07/26 US$58.07 -2.67% 3,780,416
21/07/26 US$59.66 +0.29% 4,357,386
20/07/26 US$59.49 -3.77% 4,967,920
17/07/26 US$61.82 -2.11% 4,551,991
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
57.02USD
Average target price
49.37USD
Spread / Average Target
-13.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock